Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Studies have found that patients lose around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo Nordisk's A/S (NYSE: NVO) Wegovy. Hims will ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.